savient pharmaceuticals

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

First Trust Consumer Staples AlphaDEX (NYSE: FXG) is up more than 20% year to date. The investment seeks results that correspond generally to the price and yield of an equity index called the StrataQuant Consumer Staples Index. Top holdings include Green Mountain Coffee Roasters (NASDAQ: GMCR),...

According to Citadel Securities, Savient Pharmaceuticals (NASDAQ: SVNT) Neutral rating is reiterated. Citadel Securities said that the FDA's Arthritis Drugs Advisory Committee voted 11-1 against approval of Novartis' Ilaris for the treatment of gout flares in patients with an inadequate response...

Citadel is out with its report today on Savient Pharmaceuticals (NASDAQ: SVNT), downgrading SVNT to Neutral. In a note to clients, Citadel writes, "With the slow ramp for Krystexxa in the U.S., and with a lack of meaningful catalysts until late 2011 / early 2012, we are downgrading SVNT shares to...

Citadel Securities has downgraded Savient Pharmaceuticals (NASDAQ: SVNT) from Buy to Neutral and has established a $9 price target.

Global Hunter Securities is maintaining its Buy rating on shares of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT). “Our rating is based on the drug's efficacy profile, industry checks and favorable valuation,” Global Hunter Securities writes. “We continue to believe KRYSTEXXA could be a best-in-...

Savient Pharmaceuticals Inc. (NASDAQ: SVNT) announced that the drug's wholesale acquisition cost (WAC) will be $2,300 per 8mg vial, which equates to $59,800/yr (8mg dosed every 2 wks). “This is higher than our estimate of $40k/yr and consensus of ~$32k/yr (range ~$20k-$50k),” J.P. Morgan writes. “...

Collins Stewart has published its research report today on Savient Pharmaceuticals (NasdaqGM: SVNT) in the lead up to the formal launch of Krystexxa. Collins Stewart writes, "Yesterday at ACR, SVNT presented Krystexxa P3 OLE data in chronic gout patients. We are encouraged that patients treated...

Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) has its Overweight rating reiterated by JP Morgan following the Tuesday (9/14) evening announcement that the FDA has approved Krystexxa for the treatment of gout, JP Morgan reports, and the focus is expected to turn to the company's strategies concerning...